-transparent.png){kind=logo}
To investigate an optimal administration method in combination chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP), the clinical results of this combination therapy are reviewed. The overall response rate of this combination is 30-50%, and these results are equivalent to those of conventional combination therapy for gastric cancer. It is expected that this combination will become the standard chemotherapy for gastric cancer. Although there are several schedules of 5-FU/ CDDP combination based on the biochemical modulation theory, there are no significant differences among the individual response rates. Therefore, the schedule of this combination should change depending on the clinical condition of the patient and so on. Low-dose CDDP administration is useful, because of fewer side effects. Bolus administration of 5-FU should be considered especially for gastric cancer.
Y Maeda, and
T Sasaki
January 2007,
Anticancer research,
Y Maeda, and
T Sasaki
January 1999,
Hepato-gastroenterology,
Y Maeda, and
T Sasaki
March 1985,
Gynecologic oncology,
Y Maeda, and
T Sasaki
September 1989,
Hinyokika kiyo. Acta urologica Japonica,
Y Maeda, and
T Sasaki
July 2001,
Cancer chemotherapy and pharmacology,
Y Maeda, and
T Sasaki
January 2010,
Advances in medical sciences,
Y Maeda, and
T Sasaki
January 1987,
The Korean journal of internal medicine,
Y Maeda, and
T Sasaki
August 2008,
Journal of Korean medical science,
Y Maeda, and
T Sasaki
March 2009,
Cancer research and treatment,
Y Maeda, and
T Sasaki
January 2009,
Hepato-gastroenterology,
